look news india
Wednesday (20 May 2026) was a very tough and profitable day for the investors of pharma sector giant Zydus Lifesciences. The spectacular fourth quarter (Q4) results and the company’s strong diplomatic announcement of share buyback of ₹1,100 crore have created a stir in the market.
On the basis of these cult positive news, Zydus shares jumped more than 7% on the National Stock Exchange (NSE) to close at ₹ 1,093.65, which is its new 52-week high. Strong profits and excellent future prospects have strongly strengthened investors’ confidence in this stock.
Cult Financial Results for March 2026 Quarter (Q4)
The company has recorded a strong all-round performance in the last quarter of the financial year 2025-26:
Sharp jump in net profit: Consolidated Net Profit of Zydus Lifesciences on annual basis 14.6% increase to ₹1,592.9 crore It is done. This figure was ₹1,390.5 crore in the same quarter last year.
Revenue: The total operating income of the company also increased significantly in the quarter under review. ₹7,587 crore Reached cult level.
Wonders of Consumer Wellness: Its ‘Consumer Wellness’ business made the biggest strategic contribution to this rapid growth of the company. The segment’s revenue jumped hugely from ₹908 crore in one go ₹1,463 crore passed beyond.
Diplomatic mathematics of share buyback of ₹1,100 crore
Zydus’s board has diplomatically approved a buyback for shareholders at a steep premium, sparking a rush to scoop up shares in the market:
Strong statement from the Managing Director: Expressing diplomatic satisfaction over the financial results, the company’s MD Sharvil Patel said that the financial year 2026 has proved to be a strong and milestone for the company. We have achieved our cult targets on both revenue and profit fronts. Our pipeline of new medicines in the US market, particularly Rolvedon, Beizray and gCopaxone Strong launches like these will further accelerate our growth in the times to come.
Strict diplomatic analysis of brokerage houses
Leading brokerage houses in India and abroad have shared their different bitter and sweet opinions on this cult emergence of Zydus Lifesciences:
Nuvama Wealth Management (Nuvama): He upgraded the stock’s rating to Zydus given its strong business model and continued strong earnings visibility. upgrade Have done.
Motilal Oswal: The brokerage firm has sharply raised its earnings estimates for fiscal years 2027 and 2028 given the company’s portfolio of ‘limited-competition’ (low-competition) cult products in the US market.
JM Financial: However, JM Financial is a bit more concerned, saying that increased competition from generic drugs in the US market could put strong diplomatic pressure on the company’s margins in the long run.
Despite this, due to the strong buyback support and the cult boom coming in the healthcare sector, the overall mood of the market seems to be leaning in favor of Zydus Lifesciences.